Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 11/2010

01.11.2010 | Article

Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007

verfasst von: J. J. Yan, J. J. Wu, C. C. Lee, W. C. Ko, F. C. Yang

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

The present study was conducted to investigate the prevalence and characteristics of ertapenem-nonsusceptible (ETP-NS) Escherichia coli in a Taiwanese university. A total of 9,722 isolates collected in 1999, 2003, 2005, and 2007 were examined. Overall, 1.0% of all isolates from 66 patients were interpreted as ETP-NS on the basis of the disk diffusion test result. Most of these isolates were clonally unrelated and showed low-level ertapenem resistance, the production of CMY-2 cephalosporinase (86.4%), and decreased expression of the OmpF (97.0%) and/or OmpC (56.1%) porins. No carbapenemase was detected. The decreased porin expression was associated with disruptions of ompF or ompC in only about one-third of the ETP-NS isolates. During the study period, the prevalence of ETP-NS strains increased from 0.1 to 1.7%, accompanying an increase (0.8 to 17.6%) in the prevalence of CMY-2 producers. Coexistent or pre-existing clonally related ertapenem-susceptible (ETP-S) E. coli isolates were identified in 47.0% of all case patients, and almost all of the ETP-S isolates had the same β-lactamases as the ETP-NS isolates. Our study results suggest the restricted use of extended-spectrum cephalosporins to hinder the emergence and prevalence of carbapenem resistance in E. coli, which may arise by the accumulation of multiple resistance determinants.
Literatur
1.
Zurück zum Zitat Edwards SJ, Clarke MJ, Wordsworth S, Emmas CE (2008) Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials. Eur J Clin Microbiol Infect Dis 27:531–543CrossRefPubMed Edwards SJ, Clarke MJ, Wordsworth S, Emmas CE (2008) Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials. Eur J Clin Microbiol Infect Dis 27:531–543CrossRefPubMed
2.
Zurück zum Zitat Nordmann P, Cuzon G, Naas T (2009) The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236CrossRefPubMed Nordmann P, Cuzon G, Naas T (2009) The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236CrossRefPubMed
3.
Zurück zum Zitat Queenan AM, Bush K (2007) Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458CrossRefPubMed Queenan AM, Bush K (2007) Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458CrossRefPubMed
4.
Zurück zum Zitat Gröbner S, Linke D, Schütz W, Fladerer C, Madlung J, Autenrieth IB, Witte W, Pfeifer Y (2009) Emergence of carbapenem-non-susceptible extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany. J Med Microbiol 58:912–922CrossRefPubMed Gröbner S, Linke D, Schütz W, Fladerer C, Madlung J, Autenrieth IB, Witte W, Pfeifer Y (2009) Emergence of carbapenem-non-susceptible extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany. J Med Microbiol 58:912–922CrossRefPubMed
5.
Zurück zum Zitat Livermore DM, Hope R, Brick G, Lillie M, Reynolds R; BSAC Working Parties on Resistance Surveillance (2008) Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother 62(Suppl 2):ii41–ii54CrossRefPubMed Livermore DM, Hope R, Brick G, Lillie M, Reynolds R; BSAC Working Parties on Resistance Surveillance (2008) Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother 62(Suppl 2):ii41–ii54CrossRefPubMed
6.
Zurück zum Zitat Doumith M, Ellington MJ, Livermore DM, Woodford N (2009) Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659–667CrossRefPubMed Doumith M, Ellington MJ, Livermore DM, Woodford N (2009) Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659–667CrossRefPubMed
7.
Zurück zum Zitat Liu YF, Yan JJ, Ko WC, Tsai SH, Wu JJ (2008) Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan. J Antimicrob Chemother 61:1020–1023CrossRefPubMed Liu YF, Yan JJ, Ko WC, Tsai SH, Wu JJ (2008) Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan. J Antimicrob Chemother 61:1020–1023CrossRefPubMed
8.
Zurück zum Zitat Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P (2007) Ertapenem resistance of Escherichia coli. Emerg Infect Dis 13:315–317CrossRefPubMed Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P (2007) Ertapenem resistance of Escherichia coli. Emerg Infect Dis 13:315–317CrossRefPubMed
9.
Zurück zum Zitat Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, Saavedra JM, Pérez-Vázquez M, García-Cobos S, Martínez-Martínez L, Campos J (2008) Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 32:534–537CrossRefPubMed Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, Saavedra JM, Pérez-Vázquez M, García-Cobos S, Martínez-Martínez L, Campos J (2008) Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 32:534–537CrossRefPubMed
10.
Zurück zum Zitat Wexler HM (2004) In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 53(Suppl 2):ii11–ii21CrossRefPubMed Wexler HM (2004) In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 53(Suppl 2):ii11–ii21CrossRefPubMed
11.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. CLSI document M100-S19. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. CLSI document M100-S19. CLSI, Wayne, PA
12.
Zurück zum Zitat Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239PubMed Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239PubMed
13.
Zurück zum Zitat Versalovic J, Koeuth T, Lupski JR (1991) Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 19:6823–6831CrossRefPubMed Versalovic J, Koeuth T, Lupski JR (1991) Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 19:6823–6831CrossRefPubMed
14.
Zurück zum Zitat Yan JJ, Ko WC, Wu HM, Tsai SH, Chuang CL, Wu JJ (2004) Complexity of Klebsiella pneumoniae isolates resistant to both cephamycins and extended-spectrum cephalosporins at a teaching hospital in Taiwan. J Clin Microbiol 42:5337–5340CrossRefPubMed Yan JJ, Ko WC, Wu HM, Tsai SH, Chuang CL, Wu JJ (2004) Complexity of Klebsiella pneumoniae isolates resistant to both cephamycins and extended-spectrum cephalosporins at a teaching hospital in Taiwan. J Clin Microbiol 42:5337–5340CrossRefPubMed
15.
Zurück zum Zitat Song W, Jeong SH, Kim JS, Kim HS, Shin DH, Roh KH, Lee KM (2007) Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis. Diagn Microbiol Infect Dis 57:315–318CrossRefPubMed Song W, Jeong SH, Kim JS, Kim HS, Shin DH, Roh KH, Lee KM (2007) Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis. Diagn Microbiol Infect Dis 57:315–318CrossRefPubMed
16.
Zurück zum Zitat Yan JJ, Wu JJ, Tsai SH, Chuang CL (2004) Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-β-lactamases in gram-negative bacilli. Diagn Microbiol Infect Dis 49:5–11CrossRefPubMed Yan JJ, Wu JJ, Tsai SH, Chuang CL (2004) Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-β-lactamases in gram-negative bacilli. Diagn Microbiol Infect Dis 49:5–11CrossRefPubMed
17.
Zurück zum Zitat Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC (2001) Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161CrossRefPubMed Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC (2001) Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161CrossRefPubMed
18.
Zurück zum Zitat Yan JJ, Ko WC, Tsai SH, Wu HM, Jin YT, Wu JJ (2000) Dissemination of CTX-M-3 and CMY-2 β-lactamases among clinical isolates of Escherichia coli in southern Taiwan. J Clin Microbiol 38:4320–4325PubMed Yan JJ, Ko WC, Tsai SH, Wu HM, Jin YT, Wu JJ (2000) Dissemination of CTX-M-3 and CMY-2 β-lactamases among clinical isolates of Escherichia coli in southern Taiwan. J Clin Microbiol 38:4320–4325PubMed
19.
Zurück zum Zitat Yan JJ, Ko WC, Wu JJ, Tsai SH, Chuang CL (2004) Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital. J Clin Microbiol 42:3329–3332CrossRefPubMed Yan JJ, Ko WC, Wu JJ, Tsai SH, Chuang CL (2004) Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital. J Clin Microbiol 42:3329–3332CrossRefPubMed
20.
Zurück zum Zitat Philippon A, Arlet G, Jacoby GA (2002) Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 46:1–11CrossRefPubMed Philippon A, Arlet G, Jacoby GA (2002) Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 46:1–11CrossRefPubMed
21.
Zurück zum Zitat Poirel L, Héritier C, Spicq C, Nordmann P (2004) In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 42:3831–3833CrossRefPubMed Poirel L, Héritier C, Spicq C, Nordmann P (2004) In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 42:3831–3833CrossRefPubMed
22.
Zurück zum Zitat Mammeri H, Nordmann P, Berkani A, Eb F (2008) Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett 282:238–240CrossRefPubMed Mammeri H, Nordmann P, Berkani A, Eb F (2008) Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett 282:238–240CrossRefPubMed
23.
Zurück zum Zitat Szabó D, Silveira F, Hujer AM, Bonomo RA, Hujer KM, Marsh JW, Bethel CR, Doi Y, Deeley K, Paterson DL (2006) Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother 50:2833–2835CrossRefPubMed Szabó D, Silveira F, Hujer AM, Bonomo RA, Hujer KM, Marsh JW, Bethel CR, Doi Y, Deeley K, Paterson DL (2006) Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother 50:2833–2835CrossRefPubMed
24.
Zurück zum Zitat Pournaras S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, Legakis NJ, Maniatis AN (2005) Spread of efflux pump-overexpressing, non-metallo-β-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with bla VIM endemicity. J Antimicrob Chemother 56:761–764CrossRefPubMed Pournaras S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, Legakis NJ, Maniatis AN (2005) Spread of efflux pump-overexpressing, non-metallo-β-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with bla VIM endemicity. J Antimicrob Chemother 56:761–764CrossRefPubMed
Metadaten
Titel
Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007
verfasst von
J. J. Yan
J. J. Wu
C. C. Lee
W. C. Ko
F. C. Yang
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2010
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-1020-1

Weitere Artikel der Ausgabe 11/2010

European Journal of Clinical Microbiology & Infectious Diseases 11/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.